CA2301921A1 - Compositions contenant du polyethylene glycol et leurs utilisations - Google Patents

Compositions contenant du polyethylene glycol et leurs utilisations Download PDF

Info

Publication number
CA2301921A1
CA2301921A1 CA002301921A CA2301921A CA2301921A1 CA 2301921 A1 CA2301921 A1 CA 2301921A1 CA 002301921 A CA002301921 A CA 002301921A CA 2301921 A CA2301921 A CA 2301921A CA 2301921 A1 CA2301921 A1 CA 2301921A1
Authority
CA
Canada
Prior art keywords
peg
composition
cells
based molecule
peg based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002301921A
Other languages
English (en)
Inventor
John Graham Goddard
John Statler
Matt Foehr
Donald Picker
Cindy Feustel
Winston Wincomb
Ian Bathurst
Samuil Umansky
L. David Tomei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
LXR Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LXR Biotechnology Inc filed Critical LXR Biotechnology Inc
Publication of CA2301921A1 publication Critical patent/CA2301921A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention concerne des compositions thérapeutiques contenant du polyéthylène glycol, des procédés de production des compositions et leurs procédés d'utilisation.
CA002301921A 1997-08-20 1998-08-20 Compositions contenant du polyethylene glycol et leurs utilisations Abandoned CA2301921A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5674497P 1997-08-20 1997-08-20
US60/056,744 1997-08-20
PCT/US1998/017258 WO1999008514A1 (fr) 1997-08-20 1998-08-20 Compositions contenant du polyethylene glycol et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2301921A1 true CA2301921A1 (fr) 1999-02-25

Family

ID=22006334

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002301921A Abandoned CA2301921A1 (fr) 1997-08-20 1998-08-20 Compositions contenant du polyethylene glycol et leurs utilisations

Country Status (3)

Country Link
AU (1) AU9027298A (fr)
CA (1) CA2301921A1 (fr)
WO (1) WO1999008514A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047101A2 (fr) * 1998-03-18 1999-09-23 Lxr Biotechnology, Inc. Compositions contenant des acides lysophosphatidiques qui inhibent l'apoptose et leurs utilisations
FR2790641B1 (fr) * 1999-03-10 2005-02-25 Cair L G L Liquide de conservation de tissu humain ou animal, notamment de veines
FR2793651B1 (fr) * 1999-05-18 2003-05-16 Cair L G L Solution aqueuse de conservation de tissus et d'organes
US6380177B1 (en) 1999-06-25 2002-04-30 Atairgin Technologies, Inc. LPA analogs as agonists of the Edg2 LPA receptor
AU7057700A (en) * 1999-08-18 2001-03-13 Atairgin Technologies, Inc. Compounds which modulate the activity of an lpa receptor
JP2004506604A (ja) 2000-03-17 2004-03-04 ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレイション Ｌｐａ受容体作用薬および拮抗薬ならびにこれらの使用法
BR0215954A (pt) 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
WO2004071451A2 (fr) 2003-02-12 2004-08-26 Ceremed, Inc. Copolymeres d'oxyde d'alkylene aleatoires destines a des utilisations medicales et chirurgicales
JP2007533755A (ja) * 2004-04-20 2007-11-22 ザ ユニヴァーシティ オヴ シカゴ 高分子量ｐｅｇ様化合物を含む治療薬送達システム
EP2211872A4 (fr) * 2007-11-02 2012-01-04 Univ British Columbia Polyglycérol hyperramifié pour améliorer la fonction cardiaque
EP3677261B8 (fr) 2010-09-23 2023-07-19 Leading BioSciences, Inc. Administration d'inhibiteurs de la protéase sérine dans l'estomac
KR102397379B1 (ko) 2014-03-25 2022-05-13 리딩 바이오사이언시즈, 인크. 자가소화의 치료용의 조성물
ES2949977T3 (es) * 2018-11-30 2023-10-04 Icoat Medical Ab Tratamiento de órganos ex vivo con moléculas de PEG-fosfolípido
US11007227B2 (en) 2019-03-29 2021-05-18 Virginia Commonwealth University Compositions and methods for restoring or increasing tissue perfusion
WO2021061687A1 (fr) * 2019-09-27 2021-04-01 Virginia Commonwealth University Compositions et procédés de restauration ou d'augmentation de perfusion tissulaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63500517A (ja) * 1985-06-20 1988-02-25 フア−マコン，インコ−ポレイテツド 薬用脱毛防止錯化合物および組成物
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US5171264A (en) * 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
CA2101361A1 (fr) * 1992-08-27 1994-02-28 Robert A. Snow Substances proteiniques a action biologique liees a un oxyde de polyalkylene a faible teneur en diols
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
EP0850064A1 (fr) * 1995-09-14 1998-07-01 Lxr Biotechnology Inc. Compositions ayant une activite anti-apoptotique et contenant un melange de phospholipides

Also Published As

Publication number Publication date
AU9027298A (en) 1999-03-08
WO1999008514A1 (fr) 1999-02-25

Similar Documents

Publication Publication Date Title
US6949529B2 (en) Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US7259273B1 (en) Compositions containing lysophosphotidic acids which inhabit apoptosis and uses thereof
CA2301921A1 (fr) Compositions contenant du polyethylene glycol et leurs utilisations
US7537885B2 (en) Composition for maintaining organ and cell viability
AU2003229028B2 (en) A direct cellular energy delivery system
US5374624A (en) Fluorocarbon blood substitute
CA2284142C (fr) Compositions contenant des acides lysophosphotidiques inhibant l'apoptose, et leurs utilisations
US20110311442A1 (en) Direct cellular energy delivery system
JP2008101009A (ja) リン脂質の混合物を含む抗アポトーシス活性を有する組成物
WO1999047101A2 (fr) Compositions contenant des acides lysophosphatidiques qui inhibent l'apoptose et leurs utilisations
US20060063738A1 (en) Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
AU2006252244A1 (en) Compositions containing polyethylene glycol and uses thereof
AU2002309014B2 (en) Compositions containing Lysophosphotidic Acids Which Inhibit Apoptosis and uses Thereof
EP1313449B1 (fr) Emulsion structuree d'amphotericine b
US7157082B2 (en) Cardioprotective therapies based on enzymatic elimination of lipid peroxides by allene oxide synthase
ZA200409170B (en) A direct cellular energy delivery system.

Legal Events

Date Code Title Description
FZDE Discontinued